ERBB2 and neoplasm: This vaccinal effect of trastuzumab is likely mediated either by antigen-presenting cell cross-presentation of trastuzumab-bound HER2, which has been released into the tumor microenvironment and/or by trastuzumab-induced endocytosis and MHC class I presentation directly on tumor cells [109].